Ascendis Pharma
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful.
Launch date
Employees
Market cap
AUD10.1b
Enterprise valuation
AUD10.8b (Public information from Sep 2024)
Share price
$148.88 ASND
Company register number HRB 337385 (Mannheim)
Gentofte Municipality Capital Region of Denmark (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.0m | 7.8m | 51.2m | 267m | 402m | 702m | 1.2b |
| % growth | (48 %) | 12 % | 558 % | 421 % | 51 % | 74 % | 68 % |
| EBITDA | (329m) | (424m) | (558m) | (438m) | (236m) | (43.6m) | 223m |
| % EBITDA margin | (4730 %) | (5447 %) | (1091 %) | (164 %) | (59 %) | (6 %) | 19 % |
| Profit | (419m) | (384m) | (583m) | (481m) | (304m) | (28.3m) | 351m |
| % profit margin | (6026 %) | (4932 %) | (1140 %) | (181 %) | (76 %) | (4 %) | 30 % |
| EV / revenue | 968.9x | 789.0x | 120.3x | 24.7x | 19.0x | 10.9x | 6.2x |
| EV / EBITDA | -20.5x | -14.5x | -11.0x | -15.0x | -32.4x | -175.2x | 32.7x |
| R&D budget | 261m | 296m | 380m | 413m | - | - | - |
| R&D % of revenue | 3752 % | 3804 % | 742 % | 155 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€17.6m | Series A | ||
$60.0m | Series C | ||
| N/A | $108m Valuation: $373m | IPO | |
N/A | Post IPO Equity | ||
* | N/A | $569m | Post IPO Equity |
* | N/A | $500m | Post IPO Debt |
* | $150m | Post IPO Debt | |
| Total Funding | AUD123m | ||
Related Content
Recent News about Ascendis Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
